A £1.2m Long Covid trial with the University of Exeter gave 73 patients a five-day antiviral drip. Most reported less fatigue, and a larger trial is next.
A £1.2m clinical trial run with the University of Exeter has shown that people with Long Covid can be given an antiviral drug through a drip for five days in a row, and that most of the 73 patients who took part reported less fatigue, a better quality of life and a longer walking distance afterwards. The researchers say the next step is a larger randomised controlled trial to find out whether the drug actually works.
Overview
- What: the ERASE trial tested whether an antiviral drug given intravenously could be used to treat Long Covid.
- Who: led by the University of Derby with the University of Exeter, and managed by the University of Plymouth’s Peninsula Clinical Trials Unit, in collaboration with Aston University.
- Exeter’s part: patients were assessed at the University of Exeter, and clinical teams from the Royal Devon University Healthcare NHS Foundation Trust gave the treatment alongside teams in Derby.
- Patients: 73, each treated for five consecutive days.
- Result: the treatment and the assessments were safe and feasible. The trial was not designed to show whether the drug works.
- Next: the team is calling for a larger randomised controlled trial.
What the trial found
The trial began in September 2024 and was set up to test feasibility: whether a five-day intravenous course, and the assessments needed to judge it, could be delivered to people with Long Covid at all. According to the research team, it found that:
- the five-day intravenous treatment regimen could be successfully delivered;
- participants were able to complete the clinical assessments the research needed;
- the study produced the information needed to plan a larger randomised controlled trial.
The team also reported encouraging changes in what it calls exploratory measures, with most participants reporting reductions in fatigue, improved quality of life and an increased walking distance in a timed walking test.
Professor Mark Faghy, Visiting Professor at the University of Derby and Professor of Clinical Exercise Science at Loughborough University, who led the study, said:
“These findings are an important step forward in our research into potential treatments for Long Covid. We have shown that it is possible to deliver this intravenous antiviral treatment and undertake the assessments needed to evaluate it in people with Long Covid.
“We also saw encouraging changes in measures including fatigue, functional capacity, quality of life and commonly reported symptoms. While ERASE was not designed to tell us whether the treatment caused those changes or whether the treatment works, the findings give us a strong rationale for carrying out a larger randomised controlled trial that will allow us to answer that question.”
The Exeter side
Professor David Strain, a clinician at the University of Exeter and a co-author of the study, said:
“We’re still seeing large numbers of people who are debilitated by Long Covid in clinic. Our study is a promising step to indicate that the specific antiviral we tested may offer some relief to symptoms, though we now need confirmation in much larger clinical trials to evaluate how effective it is. Our advice to people with long Covid remains to talk to your GP and follow clinical guidance.”
Before treatment, the 73 patients went through a series of assessments at the University of Derby’s specialist facilities and at the University of Exeter. The drug was then given by clinical teams from University Hospitals of Derby and Burton NHS Foundation Trust and the Royal Devon University Healthcare NHS Foundation Trust.
Dr Tom Bewick, Principal Investigator for the Derby trust, said more than 50 people with Long Covid in Derbyshire were selected to receive the five-day course at the Royal Derby Hospital. “Following the successful delivery of this pilot, it is the goal to expand this research in the future in a larger randomised trial,” he said.
Why a bigger trial comes next
More than two million people in the UK are estimated to be living with Long Covid, according to the research team. Symptoms vary widely and include extreme fatigue, breathlessness, palpitations and brain fog.
Professor Victoria Allgar, Director of the Peninsula Clinical Trials Unit and one of several Plymouth authors on the study, said:
“The successful completion of ERASE demonstrates why feasibility studies are so important. Before investing in a large-scale efficacy trial, we need confidence that recruitment, treatment delivery, data collection and participant follow-up can all be achieved. The findings from ERASE show that these key elements are workable in people living with Long Covid and provide the foundations for a future definitive trial.”
Professor Faghy said the team had worked closely with patients throughout. “We have seen first-hand the considerable impact Long Covid can have on people’s lives. The next step is to build on what we have learned and rigorously test whether this approach can benefit patients,” he said.
ERASE is part of a wider programme of research led by the University of Derby into the causes and impacts of Long Covid.
Source: University of Exeter press office.
Have your say